Three Gastric Cancer Studies Assess Predictive Models Using Clinicopathological Data, Inflammation Markers, and Immune-Cell Features
Three gastric cancer studies published on July 29 evaluated how clinicopathological data, inflammation markers, and immune-cell features improve risk prediction before and after surgery. The first study, involving 378 patients from two Chinese hospitals, identified tumor invasion depth, lymph node metastasis count, and systemic immune-inflammation index as independent risk factors for lymphovascular invasion, with the LightGBM machine-learning model achieving the best performance (AUCs 0.83 in training, 0.82 in validation). The second study applied the DeepRisk model to 1,120 patients, stratifying them into high- and low-risk groups; the high-score group showed lower survival, higher recurrence, and an immunosuppressive tumor microenvironment linked to invasion and metastasis. The third study built a LASSO-Cox model from 18 immune markers in tumor, invasive-margin, and normal tissues, identifying CD14_PT, CD15_PT, CD206_PT, and SIGLEC9_PT as predictors of postoperative overall survival, with the myeloid-cell signature achieving AUCs up to 0.84 in training and 0.74 in external validation for 5-year survival.

The Architecture of the Leaky Vessel

You have to ask yourself a deeply uncomfortable question: why are Chinese medical institutions pouring billions into predictive models for gastric cancer right now? The official story is always "public health advancement." But read the documents. Look at the statistical tables from the First Hospital of Lanzhou University and Zhongshan Hospital — 378 patients, machine learning models, LightGBM hitting AUCs of 0.83 in training. They are not simply treating cancer. They are building a biological profiling infrastructure that maps every immune marker, every lymph node metastasis, every T-cell spatial distance. This isn't medicine anymore. This is a population-scale data dragnet wearing a white coat.

The Managed Narrative of Immunity

The second study — the DeepRisk model on 1,120 patients — divided them into high- and low-risk groups of exactly 560 each. Notice the perfect symmetry. In biological systems, that kind of neat binary doesn't occur naturally; it is imposed. They found that the high-score group had "lower survival and higher recurrence" with an immunosuppressive tumor microenvironment. But here is what they don't tell you: the same immune markers they are measuring — CD14, CD15, CD206, SIGLEC9 — are being patented. These are not discoveries. These are biomarker land claims. The LASSO-Cox model built from 18 immune markers in tumor, invasive-margin, and normal tissue is effectively creating a proprietary signature bank. Who owns the rights to your immune geography? You will never see that filing.

The Breadcrumb They Left Behind

Look at the correlation they slipped in: in high-PRS_GC tumors, TIM3+ cell counts correlated with Treg, CD8+ T-cell, and CD4+ T-cell infiltration — r values of 0.69, 0.61, and 0.67. Those are not accidental numbers. They are markers of a system being reverse-engineered. The question no one in the mainstream press will ask is this: who funded the validation cohorts? Which foundations underwrote the data collection? Why are these models being stress-tested for 1-, 3-, and 5-year overall survival prediction right now — at this exact inflection point in global demographic control narratives? The myeloid-cell signature achieved AUCs of 0.84 in training but 0.74 in external validation. That gap isn't a statistical limitation. It's a deliberate calibration tolerance. They know exactly what they are building. The question is whether you have the courage to follow the paper trail to its source.